Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
暂无分享,去创建一个
David S. Park | Hymie Anisman | H. Anisman | R. Slack | S. Przedborski | S. Hayley | V. Jackson-Lewis | Patrice D Smith | Serge Przedborski | Patrice D. Smith | Vernice Jackson-Lewis | Stephen J Crocker | Shawn Hayley | David S Park | Tanaya Shree | Matthew Mount | Ruth Slack | S. Crocker | T. Shree | MatthewP . Mount
[1] J. Qian,et al. Behavioral and Cellular Protection of Rat Dopaminergic Neurons by an Adenoviral Vector Encoding Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.
[2] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[3] I. Herr,et al. CD95 Ligand (Fas-L/APO-1L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mediate Ischemia-Induced Apoptosis in Neurons , 1999, The Journal of Neuroscience.
[4] R. Adar,et al. Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. , 1996, Behring Institute Mitteilungen.
[5] S. Kish,et al. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.
[6] O. Lindvall,et al. Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals , 1975, Brain Research.
[7] Y. Agid,et al. FADD: A link between TNF family receptors and caspases in Parkinson’s disease , 2002, Neurology.
[8] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[9] B. Puig,et al. Fas and Fas ligand expression in Alzheimer's disease , 2001, Acta Neuropathologica.
[10] R. Pawlinski,et al. Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods , 2001, Journal of neuroscience research.
[11] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[12] F. Herrera,et al. Protective effect of melatonin in a chronic experimental model of Parkinson’s disease , 2002, Brain Research.
[13] D. Perl,et al. A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.
[14] B. Bush,et al. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. , 1986, Journal of chromatography.
[15] David S. Park,et al. Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease , 2003, The Journal of Neuroscience.
[16] S. Korsmeyer,et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] David S. Park,et al. c-Jun mediates axotomy-induced dopamine neuron death in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Glowinski,et al. Dendritic release of dopamine in the substantia nigra , 1981, Nature.
[19] M. Greenberg,et al. β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.
[20] P. Riederer,et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues , 1996, Neuroscience Letters.
[21] S. Daniel,et al. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[22] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[23] Hae-Ock Lee,et al. Biology of FasL. , 2003, Cytokine & growth factor reviews.
[24] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[25] Chulhee Choi,et al. Fas Engagement Increases Expression of Interleukin-6 in Human Glioma Cells , 2004, Journal of Neuro-Oncology.
[26] J. Petitto,et al. Relationship between the development of autoimmunity and sensorimotor gating in MRL-lpr mice with reduced IL-2 production , 2002, Neuroscience Letters.
[27] J. Schulz,et al. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. , 2003, Toxicology letters.
[28] T. Hunter,et al. Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury , 1998, The Journal of Neuroscience.
[29] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Kiener,et al. Fas (CD95) Induces Proinflammatory Cytokine Responses by Human Monocytes and Monocyte-Derived Macrophages12 , 2003, The Journal of Immunology.
[31] I. Kopin,et al. 6-Fluorocatecholamines as false adrenergic neurotransmitters. , 1983, The Journal of pharmacology and experimental therapeutics.
[32] R. Faull,et al. Prolonged expression of Fos-related antigens, Jun B and TrkB in dopamine-denervated striatal neurons. , 1995, Brain research. Molecular brain research.
[33] R. Stead,et al. A behavioral profile of autoimmune lupus-prone MRL mice , 1992, Brain, Behavior, and Immunity.
[34] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[35] S. Ju,et al. Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors1 , 2001, The Journal of Immunology.
[36] X. Xu,et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. , 2001, Cancer research.
[37] A. Cross,et al. Role of Fas–FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease , 1999, Journal of Neuroimmunology.
[38] E. Hirsch,et al. Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis , 2001, The Journal of Neuroscience.
[39] M. Abercrombie. Estimation of nuclear population from microtome sections , 1946, The Anatomical record.
[40] S. Parvez,et al. Apoptotic molecules and MPTP-induced cell death. , 2002, Neurotoxicology and teratology.
[41] K. Jellinger,et al. Recent developments in the pathology of Parkinson's disease. , 2002, Journal of neural transmission. Supplementum.
[42] J. Bennett,et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[43] S. Nagata,et al. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.
[44] A. Grace,et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.
[45] Andrzej Członkowski,et al. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[46] R. Burke,et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[47] R. Merchant,et al. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. , 1999, Journal of immunology.
[48] H. Ichinose,et al. Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.
[49] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Onrust,et al. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. , 2000, Gene.
[51] Y. Agid,et al. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. , 1997, Histology and histopathology.